An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
Prostate cancer treatments carry different risks. Dr. Fernando Bianco argues for informed decisions that balance cancer ...
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with ...
Briganti and colleagues concluded that, together with the main PROTEUS study, the substudy supports 1-year perioperative apalutamide plus ADT as a treatment option for patients with high-risk ...
Salvage radiation after surgery: If PSA rises after surgery, radiation to the area where the prostate was can still be ...
Dr. Kishore T. A , Senior Consultant, Uro Oncology & Transplant Surgery, Aster Medcity Kochi | A major 1,500-case experience ...
Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given ...
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ...
Five-year results from the NRG-GU003 Phase III trial show that a 25-fraction, five-week postoperative radiation schedule ...
A new meta-analysis of sixteen randomized controlled trials shows that prehabilitation before radical prostatectomy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results